Dr. JeenJoo “JJ” Kang is a mission-driven entrepreneur and venture investor with a track record of building innovative companies. She is the CEO and a co-founder of Appia Bio, a biotechnology company founded in 2020 focused on developing and expanding the therapeutic potential of allogeneic cell therapy in cancer. Prior to starting Appia Bio, JJ was a partner on the investment team at The Column Group, a life sciences venture capital firm. She was the founding president of Tenaya Therapeutics and served on the boards of portfolio companies Tenaya Therapeutics (NASDAQ:TNYA), Exonics Therapeutics (acquired), and Escient Pharmaceuticals. Prior to that, she worked at FibroGen in project management and corporate strategy. JJ earned a PhD in chemical biology at Caltech and a BA in chemistry from Harvard University.